Insights & news

Medicines – Publication of Regulation (EU) 2019/5 of 11 December 2018 amending Regulation (EC) No 726/2004 – Key Novelties

  • 08/01/2019
  • Articles

On 7 January 2019, the Official Journal of the European Union published a Regulation amending the EU regulatory framework governing medicinal products. The attached memorandum discusses the key changes brought about by the Regulation.


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 14/01/2019
    • Articles

    General Court of European Union Confirms Withdrawal Of Orphan Medicine Status Because Cancer Medicine Elotuzumab No Longer Offers Significant Benefit Over Alternative Treatment

    On 5 December 2018, the General Court of the European Union dismissed an action for annulment of a decision of the European Commission which had found that elotuzumab, a medicine indicated for the treatment of multiple myeloma, no longer satisfied the criteria for designation as an orphan medicinal product. Please find attached a case note which discusses this judgment.

    Read more
    • 10/01/2019
    • Articles

    Veterinary Medicinal Products - Publication of Regulation (EU) 2019/6

    After four years of negotiations, Regulation (EU) 2019/6 governing veterinary medicinal products was adopted on 11 December 2018 and officially published on 7 January 2019. The new Regulation, which will apply as of 28 January 2022, aims to establish a modern regulatory framework for veterinary medicinal products. The attached memorandum discusses its most striking features.

    Read more
    • 27/12/2018
    • Articles

    General Court Reviews New Set of Patent Settlement Agreements In Pharmaceutical Sector (Servier and Others)

    In a series of judgments earlier this month, the General Court of the European Union had again occasion to review patent settlement agreements in the pharmaceutical sector. The General Court delivered a mixed verdict in that it held that: i. as a general matter, patent settlement agreements should be encouraged and are pro-competitive; ii. settlement agreements which do not merely end litigation, but also give benefits to generic companies as a form of compensation to refrain from entering the market constitute a restriction by object of competition. iii. in limiting the relevant product market to a single active substance, the European Commission defined that market too narrowly, thus erroneously imputing a dominant position to Servier. Please find attached a case-note discussing these judgments.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *